CT120

DB18181InvestigationalCell transplant therapies

CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.

Mechanism: Pharmacologically active on B-cell receptor CD22 and B-lymphocyte antigen CD19
Curator reviewed
Code names: CT120

Resolves to

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with CT120, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.